Takeda (TYO: 4502) has submitted a New Drug Application (NDA) in Japan for a subcutaneous (SC) formulation of Entyvio (vedolizumab) as a maintenance therapy for moderately to severely active ulcerative colitis (UC).
The Japanese drugmaker proposes to make Entyvio SC available in both syringe and pen options.
Naoyoshi Hirota, head of the Takeda Development Center Japan, said: “This NDA filing is an important step in our commitment to deliver innovative medicines and treatment modalities that meet the needs of patients living with UC in Japan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze